iRhythm announces results from CAMELOT study have been published

iRhythm announced that the results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events, CAMELOT, study have been published in the American Heart Journal. The peer-reviewed manuscript, titled “Comparative Effectiveness and Healthcare Utilization for Ambulatory Cardiac Monitoring Strategies in Medicare Beneficiaries,” reveals that the Zio long-term continuous monitoring service, which features up to 14 continuous days of monitoring, was independently associated with the highest yield of clinical arrhythmia encounter diagnosis and lowest likelihood of retest. The retrospective study of almost 300,000 patients makes CAMELOT the largest published real-world comparative effectiveness analysis of ambulatory cardiac monitoring. The study found that in diagnostic-naive Medicare patients, Zio LTCM was associated with a higher diagnostic yield, ascertained by medical claims, compared to all other ACMs when looking at specified arrhythmias. The study also found that in diagnostic-naive Medicare patients, the Zio LTCM had a lower adjusted odds of retesting within 180 days compared to other ACM modalities, including LTCMs from other service providers in the same extended monitoring category. The study also found that LTCM were associated with the lowest increase in health care resource utilization and costs – including fewer emergency department visits.